A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Probuphine in Patients With Opioid Dependence
Phase of Trial: Phase III
Latest Information Update: 22 Oct 2019
Price : $35 *
At a glance
- Drugs Buprenorphine (Primary)
- Indications Opioid abuse
- Focus Registrational; Therapeutic Use
- Sponsors Titan Pharmaceuticals
- 22 Oct 2019 According to a Titan Pharmaceuticals media release, results from analysis of data from PRO-805, PRO-806, PRO-807, PRO-810 and PRO-811 Phase 3 clinical studies will be presented at the 10th American Conference on Pharmacometrics.
- 05 Mar 2014 New trial record
- 03 Mar 2014 Results have been published in the Journal of the American Medical Association (JAMA), according to a Titan Pharmaceuticals media release.